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Abstract
Background: The design of clinical immunology studies in sepsis presents several
fundamental challenges to improving the translational understanding of pathologic
mechanisms. We undertook a systematic review of bed-to-benchside studies to test
the hypothesis that variable clinical design methodologies used to investigate
immunologic function in sepsis contribute to apparently conflicting laboratory data,
and identify potential alternatives that overcome various obstacles to improve
experimental design.
Methods: We performed a systematic review of the design methodology employed
to study neutrophil function (respiratory burst), monocyte endotoxin tolerance and
lymphocyte apoptosis in the intensive care setting, over the past 15 years. We
specifically focussed on how control samples were defined, taking into account age,
gender, ethnicity, concomitant therapies, timing of sample collection and the criteria
used to diagnose sepsis.
Results: We identified 57 eligible studies, the majority of which (74%) used case–control
methodology. Healthy volunteers represented the control population selected in 83% of
studies. Comprehensive demographic data on age, gender and ethnicity were provided
in ≤48% of case control studies. Documentation of diseases associated with
immunosuppression, malignancy and immunomodulatory therapies was rare. Less than
half (44%) of studies undertook independent adjudication for the diagnosis of sepsis
while 68% provided microbiological data. The timing of sample collection was defined
by highly variable clinical criteria. By contrast, surgical studies avoided many such
confounders, although only one study in surgical patients monitored the study group
for development of sepsis.
Conclusions: We found several important and common limitations in the clinical design
of translational immunologic studies in human sepsis. Major elective surgery overcame
many of these methodological limitations. The failure of adequate clinical design in
mechanistic studies may contribute to the lack of translational therapeutic progress in
intensive care medicine.
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Background
Mortality from sepsis is persistently high, and may even be rising despite decades of
research [1,2]. Promising pre-clinical immunomodulatory therapies have failed in clinical
practice [3-5] perhaps attributable, in part, to differences between human and rodent im-
munology [6]. However, an alternative explanation is that the heterogeneous etiology, pre-
sentation and progression of human sepsis generate confounding factors that distort the
interpretation of clinical immunologic studies. Thus, the identification of appropriate con-
trols, diagnostic accuracy, demographic influences and therapies with immunomodu-
latory off-target effects are critical considerations in interpreting translational work.
We therefore systematically reviewed the clinical experimental design of studies
in three key areas of bed-to-benchside immunologic research in sepsis, focusing in
particular on comparator groups and the documentation of known confounding fac-
tors. We also explored how the investigation of immune mechanisms in other clinical
scenarios - trauma and major elective surgery - associated with the development of
sepsis may help refine experimental design.
Methods
A Pubmed search was performed for the terms ‘Neutrophil respiratory burst’ OR
‘Monocyte endotoxin tolerance’ OR ‘Lymphocyte apoptosis’ AND ‘Sepsis’ OR ‘Trauma’
OR ‘Surgery’, restricted to adult human studies published between 03 January 1998 and
03 January 2013. The abstract of each paper was manually assessed for suitability. In
vitro studies of healthy volunteer cells were excluded.
Clinical demographics
For all eligible manuscripts, we recorded the primary author, year of publication and
clinical setting. The number, age, gender, clinical severity score of subjects and their
corresponding controls, in whom the same assay of immune function was performed,
were compared. The criteria used to define sepsis - complete with evidence for micro-
biological confirmation and independent adjudication of the sepsis diagnosis - were
also recorded. Since immune cell effector function may change over the course of sep-
sis, we also recorded details of the timing of initial and subsequent blood samples, and
the reason for blood sampling itself. Given that a recent report detected differences in
genomic markers of inflammation that associate with survival within the first 24 h of
intensive care admission [7], we assessed whether samples were obtained within, or
beyond, this 24-h window. Since several commonly used therapies used in intensive
care medicine exhibit immune modulating effects, we also recorded whether common
immunomodulatory agents including antibiotics [8], glucocorticoids [9] and sedative
agents [10] were documented. Reporting of pre-existing immunosuppressive or malig-
nant disease - or their specific exclusion - was also recorded.
Study aims
The specific aims of each study were recorded with regard to the experimental context
and primary conclusion. The context within which each of the three functional assays
was studied was classified as: Pathophysiological - observational mechanistic studies
detailing evolution of the assay response in clinical samples; Experimental - use of pa-
tient samples for more detailed experimental investigations beyond the assay itself;
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Clinical outcome - correlation of outcome measure with assay response; Biomarker
comparison - correlation of alternative assay with functional assay.
Laboratory samples
We recorded whether an a priori power analysis had been performed to determine the
number of subjects/controls needed to refute the primary hypothesis. Sample timing and
key aspects of experimental technique were compared between sepsis and control sub-
jects. Associations made between immune cell function and clinical outcome were noted.
Statistics
Data are presented as mean ± SD, or median (interquartile range). Age data in primary
studies was used to construct 95% confidence intervals in order to assess whether dif-
ferences existed between control and study populations (NCSS 8, Kaysville, UT, USA).
Results
Fifty-seven eligible studies were identified, as summarised in Figure 1. Data is displayed
into 3 tables for each immune assay, titled "Principal features of studies" (Tables 1, 2
and 3), "Demographic information" (Tables 4, 5 and 6) and "Experimental conduct and
exclusion criteria" (Tables 7, 8 and 9).
Source of experimental control subjects
No studies reported a priori power analyses based on either preceding laboratory data
or ex vivo clinical research. The majority of studies (42/57; 74%) used case–control
Citations identified and screened (n=2405)
Citations excluded on basis of title and abstract (n=2335)
Papers retrieved for detailed assessment (n=70)
Papers excluded (n=13)
- Experimental readout unrelated to search terms (n=7) 
- Non-English language (n=1)
- Paediatric study population (n=5)  
Papers used in systematic review (n=57) (n.b. Ref (7) appears under two categories).
- Neutrophil respiratory burst + sepsis (n=7) (8) (9) (10) (11) (12) (13) (14) 
- Neutrophil respiratory burst + trauma (n=7) (15) (16) (17) (18) (19) (20) 
(21)
- Neutrophil respiratory burst + surgery (n=4) (22) (23) (24) (25) 
- Monocyte endotoxin tolerance + sepsis (n=11) (26) (27) (28) (29) (30)  
(31) (32) (33) (34) (35) (36)
- Monocyte endotoxin tolerance + trauma (n=1) (37) 
- Monocyte endotoxin to lerance + surgery (n=2) (38) (39)
- Lymphocyte apoptosis + sepsis (n=16) (40) (7) (41) (42) (43) (44) (45)( 46) 
(47) (48) (49) (50) (51) (52) (53) (54)
- Lymphocyte apoptosis + trauma (n=3) (55) (56) (57) 
- Lymphocyte apoptosis + surgery (n=6) (7) (58) (59) (60) (61) (62) (63) 
Figure 1 Flow diagram illustrating study identification and inclusion [11-66].
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methodology. Control samples were obtained from healthy volunteers in (35/42; 83%),
with the remainder using a variety of loosely defined clinical phenotypes (Figure 2,
Tables 1, 2 and 3). The exception was elective surgical patients, where preoperative
samples served as appropriate controls. Cohort methodology, where samples including
controls were obtained serially from the same patient, was employed in 14/57 (25%) of
studies. The majority of cohort studies were conducted in elective surgical patients
(12/14; 86%).
Table 1 Principal features of neutrophil respiratory burst studies
Author Study
population
Subjects
(n)
Control
population
Control
(n)
Experimental
context
Outcome measure
correlated with
immune readout
Santos [12] Sepsis 49 Healthy
volunteer
19 Clinical
outcome
Yes
Paunel-
Gorgulu [19]
Trauma 7 Healthy
volunteer
6 Experimental No
Bruns [13] Sepsis
(cirrhotics)
45 Healthy
volunteer
and cohort
9 and 39 Pathophysiological No
Shih [20] Trauma 32 Healthy
volunteer
Not
provided
Biomarker
comparison
Yes
Kasten [21] Trauma 3 Healthy
volunteer
3 Pathophysiological No
Valente [22] Trauma 24 Healthy
volunteer
11 Pathophysiological No
Kawasaki [26] Elective
surgery
20
(10,10)
Cohort 20 Pathophysiological No
Frohlich [27] Elective
surgery
20 Cohort 20 Experimental No
Martins [14] Sepsis 16 Healthy
volunteer
16 Pathophysiological Yes
Barth [15] Sepsis 27 Healthy
volunteer
11 Biomarker
comparison
No
Mariano [16] Sepsis
(renal
replacement
therapy)
7 Haemodialysis
patients
10 Pathophysiological No
Quaid [23] Trauma 7 Healthy
volunteer
Not
provided
Pathophysiological No
Wiezer [28] Elective
surgery
22
(6,6,10)
Cohort 22 Pathophysiological/
experimental
Yes
Ahmed [17] Sepsis 32 Healthy
volunteer
17 Pathophysiological No
Shih [29] Trauma/
surgery
18 Cohort
and healthy
volunteer
18 Pathophysiological No
Ertel [24] Trauma 10 (5,5) Elective
surgery
10 Pathophysiological No
Ogura [25] Trauma 24
(7 infected)
Cohort and
healthy
volunteer
24 and
15
Pathophysiological Yes
Pascual [18] Sepsis 23 Elective
surgery
23 Pathophysiological/
experimental
No
Subjects: values within brackets refer to subgroups within the study.
Cain et al. Intensive Care Medicine Experimental 2014, 2:6 Page 4 of 25
http://www.icm-experimental.com/content/2/1/6
Age, gender and ethnicity
Advanced age is associated with progressively impaired innate and adaptive immunity
[67]. Less than half of case control studies (20/42; 48%) reported the age distribution of
both study and control populations. In studies where age was reported, the critically ill
patients studied were often older than the control population. Female gender is associ-
ated with improved clinical outcomes following sepsis [68,69] and increased longevity
compared to males in general. Information on gender was provided in (26/42; 62%) of
case–control studies. Significant variation in the incidence of sepsis has been reported
according to ethnicity [70], which may reflect residual confounding or plausible biologic
differences in susceptibility. However, only one study reported the ethnicity of patients.
Co-morbidity
Various comorbidities ranging from cardiac failure to active malignancy are associated
with important deleterious alteration in effective immune function, independent of
those described in sepsis [71,72]. The majority of studies (34/57; 60%) excluded patients
with overt immunosuppression while a minority (8/57; 14%) excluded those with malig-
nancy (Figure 3).
Table 2 Principal features of monocyte tolerance studies
Author Study
population
Subjects
(n)
Control
population
Controls
(n)
Experimental
context
Outcome measure
correlated with
immune readout
Liu [30] Sepsis 2 Healthy
volunteer
2 Experimental No
Buttenschoen
[41]
Elective
surgery
20 Cohort 20 Pathophysiological No
Pachot [31] Sepsis 47 Healthy
volunteer
21 Pathophysiological Yes
West [32] Sepsis 7 Healthy
volunteer,
elective
surgery
and SIRS
16, 5
and 4
Pathophysiological No
Harter [33] Sepsis 21 Healthy
volunteer
12 Pathophysiological No
Flohe [40] Surgery
in trauma
patients
16 Healthy
volunteer
12 Pathophysiological No
Escoll [34] Sepsis 3 (5) Healthy
volunteer
3 Pathophysiological No
Heagy [39] ICU
patients
(sepsis)
62 Healthy
volunteer
15 Clinical outcome Yes
Calvano [35] Sepsis 18 (10) Healthy
volunteer
15 (6) Pathophysiological No
Sfeir [36] Sepsis 10 Healthy
volunteer
10 Pathophysiological No
Kawasaki [42] Elective
surgery
20 Cohort 20 Pathophysiological No
Heagy [37] Sepsis 58 Healthy
volunteer
14 Clinical outcome Yes
Bergmann [38] Sepsis 30 (2) Healthy
volunteer
12 Pathophysiological No
Subjects/controls: numbers in brackets refer to subgroups within study.
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Table 3 Principal features of lymphocyte apoptosis studies
Author Study
population
Subjects
(n)
Control
population
Controls
(n)
Experimental
context
Outcome
measure
correlated
with
immune
readout
Roger [43] Sepsis 48 Healthy
volunteer
15 Pathophysiological No
Bandyopadhyay
[58]
Trauma 113 Healthy
volunteer
? Pathophysiological No
White [11] Sepsis 60 Gram
negative
infection and
healthy
volunteer
15 and 20 Pathophysiological Yes
White [11] Elective
surgery
(infective
complications)
19 Cohort 41 “ “
Zhang [44] Sepsis 19 Healthy
volunteer
22 Pathophysiological No
Guignant [45] Sepsis 64 Healthy
volunteer
49 Pathophysiological No
Vaki [46] Sepsis 48 (68) Healthy
volunteer
20 Pathophysiological No
Slotwinski [62] Elective
surgery
50
(26, 24)
Cohort 50 Experimental/
clinical outcome
No
Gogos [47] Sepsis PN 183,
CAP 97, IA
100, PB 61,
HAP 64
N/A Pathophysiological Yes
Hoogerwerf [48] Sepsis 16 Healthy
volunteer
24 Pathophysiological No
Yousef [49] Sepsis 32 SIRS and
without SIRS
35/33 Patient outcome Yes
Turrel-Davin [50] Sepsis 13 Healthy
volunteer
15 Biomarker
comparison
No
Pelekanou [51] Sepsis VAP 36 Other
infections
32 Pathophysiology No
Papadima [61] Elective
surgery
40
(21, 19)
Cohort 40 Pathophysiological No
Delogu [52] Sepsis 16 ? ‘individuals’ Pathophysiological No
Weber [53] Sepsis 16 Non-infected
ICU and
healthy
volunteer
10 and 11 Pathophysiological No
Roth [54] Sepsis 15 Healthy
volunteer
20 Pathophysiological No
Le Tulzo [55] Sepsis 47
(25, 23)
SIRS and
healthy
volunteer
7 and 25 Pathophysiological/
clinical outcome
Yes
Hotchkiss [56] Sepsis 27 (FC 5)
(3 intraop,
24 autopsy)
Critically ill
non-septic
and trauma
16 and 25
(FC 6) (3
prospective,
13
retrospective)
Pathophysiological No
Delogu [63] Elective
surgery
18 Cohort 18 Pathophysiological No
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Clinical definition of sepsis
A high proportion of studies (26/33; 79%) defined sepsis in accordance with the ACCP/
SCCM [73,74] or Surviving Sepsis Campaign (2008 update) [75] criteria. Of those stud-
ies which used standard consensus conference criteria, (15/26, 58%) included patients
with ‘sepsis’, (20/26; 77%) included those with ‘severe sepsis’ and (24/26, 92%) included
those with ‘septic shock’. In a large minority of these 26 studies (11/26; 42%), sub-
categories defining sepsis were not compared separately, but combined. Immunologic
studies in trauma and surgical patient samples usually did not document (18/24; 75%)
whether patients developed an infection during the course of the study. In these stud-
ies, the majority (5/6) used established consensus conference criteria.
Microbiological definitions of sepsis
Independent adjudication of the definition of sepsis used in studies was undertaken in
17/57 (30%) of studies. Since recent basic laboratory studies have demonstrated that
the clinical signs/symptoms of sepsis are frequently mimicked by non-pathogenic mole-
cules [76,77], we sought to establish whether microbial evidence for sepsis was pre-
sented. Microbiological data were provided in 25/57 (44%).
Severity of critical illness
A minority of studies (19/57; 33%) provided data on organ dysfunction related to sepsis
severity, such as APACHE-II or SAPS II. When a severity index was used, a wide range
was reported within individual studies suggesting substantial heterogeneity. In studies
where mortality was reported (4/57; 7%), severity of critical illness was not reported in
those patients who survived.
Timing of experimental samples
The timing of the index blood sample obtained from septic patients was described in
the majority (26/33; 79%) of cases. However, the criteria for initial sampling were not
Table 3 Principal features of lymphocyte apoptosis studies (Continued)
Pellegrini [59] Trauma 17
(+13 burns)
Healthy
volunteer
17 Clinical outcome/
pathophysiological
(Correlate
to MODS)
Delogu [64] Surgical 15 Healthy
volunteer
10 Pathophysiological/
patient outcome
Yes
Hotchkiss [60] Trauma 10 Elective
surgery
6 (all
prospective)
Pathophysiological No
Hotchkiss [57] Sepsis 20 Non septic
prospective/
non-septic
retrospective/
prospective
trauma
splenectomy/
prospective
colectomy/
retrospective
colectomy
1/9/6/2/8 Pathophysiological No
Sasajima [65] Elective
surgery
16
(11, 5)
Cohort 16 Pathophysiological No
Sugimoto [66] Elective
surgery
10 (5, 5) Cohort 10 Pathophysiological No
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Table 4 Demographic information of neutrophil respiratory burst studies
Author Age Gender (%male) Subject
ethnicity
detailed
Severity of subject disease Subject drug exposure documentation
Subjects Controls Statistical
test result
Subjects Controls Statistical
test result
Index Score No. Groups Sedatives Antibiotics Steroids
Santos [12] 60 ± 17 55.3 ± 18 N 57 53 N N APACHE II 17 (4 to 30) 3 N N N
Gorgulu [19] 46 ± 4 33 ± 2 N* (p < 0.001) 74 59 N N Mortality 9% 1 N N N
Bruns [13] 58 (40 to 80) 45 (37 to 82); 58 (?) 0.437 82 73/48 0.341 N - 1 N N N
Shih [20] 33 ± 14 ? N 66 ? N N ISS 23 2 N N N
Kasten [21] 36 ± 2 38 ± 2 p > 0.05 100 100 p > 0.05 N ISS 23 1 N N N
Valente [22] 75 >65 N 46 ? N N ISS 15.00 1 N N N
Kawasaki [26] 52 ± 4; 54 ± 4 N/A N 70 70 p > 0.05 N ASA I to II 2 Y N N
Frohlich [27] 66 ± 10; 69 ± 6 N/A N 40 20 N N ASA I 2 Y t Y t Y t
Martins [14] 50 ± 21 31 ± 6 N* (p = 0.0011) ? ? N N Mortality 38% 2 N N N
Barth [15] N/S (36 to 82) 24 (22 to 50) N 60 36 N N Mortality 37% 1 N N N
Mariano [16] 67 ± 4 ? N ? ? N N - 1 N N N
Quaid [23] 37 (20 to 71) ? N ? ? N N ISS 24 (17 to 34) N N N
Wiezer [28] 57 ± 3; 62 ± 2;
58 ± 5
? N 83, 66, 70 N N APACHE III Graphs
(no difference)
3 N N N
Ahmed [17] 55 ± 6 36 ± 16 N* (p < 0.0001) 46 ? N N APACHE II 20 ± 1 1 N N N
Shih [29] 42 ± 19 N/S N 55 ? N N ISS 26 ± 7.2 3 N N N
Ertel [24] N/S ? N ? ? N N AIS Head 4.5 ± 0.2,
Chest 4.1 ± 0.1
1 N N N
Ogura [25] 40 ± 19 35 ± 6 N 75 ? N N ISS 31 ± 10 2 N N N
Pascual [18] 59 (27 to 81) 45 (27 to 81) p > 0.05 51 43 N N Mortality 21% 1 N N Y t
Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we
identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups
which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute
Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was
documented. A ‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.
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Table 5 Demographic information of monocyte tolerance studies
Author Age Gender (%male) Subject
ethnicity
Severity of subject disease Subject drug exposure documentation
Subjects Controls Statistical
test result
Subjects Controls Statistical
test result
Index Score No. of
groups
Sedatives Antibiotics Steroids
Liu [30] ? ? N ? ? N N ? ? 1 N N N
Buttenschoen [41] 56 (33 to 88) N/A N 70 N/A N N ? ? n/a N N N
Pachot [31] 68 (54 to 76) 51 (42 to 65) N 62 52 N N SAPS II 51 (±5) 2 N N N
West [32] N/S N/S N 42 100; 20; 56 N N ? ? 2 N N N
Harter [33] 48 ± 20 ‘Comparable’ N 71 12 N N APACHE II 13 ± 6 1 N” N N
Flohe [40] 47 ± 18 37 ± 14 N 68 50 N N ISS 39 ± 9 1 N N N
Escoll [34] 51 ± 12 49 ± 12 N ? ? N N ? ? 1 N N N
Heagy [39] 49 ± 3; 44 ± 8 ? N ? ? N N Mortality 20%, 9.6% 2 N N N
Calvano [35] 60; 61 58 N 66; 66 66 N N ? ? 2 N N Yt
Sfeir [36] 63 ± 3 50 ± 7 N* (p < 0.0001) 80 50 N N APACHE II 27 ± 5 1 N N N
Kawasaki [42] ? N/A N ? N/A N N ASA I to II 1 N N N
Heagy [37] 49 ± 21 ? N 66 ? N N ? ? 4 N N N
Bergmann [38] 60; 51 32 N ? ? N N MODS 15 ± 1, 7 ± 1 2 N N N
Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we
identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups
which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute
Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was
documented. A ‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.
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Table 6 Demographic information of lymphocyte apoptosis studies
Author Age Gender (%male) Ethnicity Severity of subject disease Subject drug exposure
documentation
Subjects Controls Statistical
test result
Subjects Controls Statistical
test result
Index Score No. of
groups
Sedatives Antibiotics Steroids
Roger [43] 63 (37 to 82) 55 (37 to 5) 0.04 50 43 0.76 N SAPS II 55 (12 to 92) 2 N Y t Y t
Bandyopadhyay
[58]
? ‘Matched’ N ? ‘Matched’ N N APACHE >21 1 N N N
White [11] 54 (72 to 80) Bacteraemia:
73 (70 to 82)
>0.05 52 Bacteraemia
40
>0.05 Y APACHE 25 (21 to 28) 2 N N N
White [11] 64 ± 2 65 ± 1 0.74 68 70 0.86 N 2 N N N
Zhang [44] 58 ± 4 59 ± 4 N 52 50 N N APACHE
II
26 ± 3 1 N Y t Y t
Guignant [45] 63 (54 to 73) ? N 68 N N SAPS II 53(39 to 64) 1 N N Y t
Vaki [46] 71 ± 2 ? N 54 ? N N APACHE
II
20 ± 9 1 (3) N N N
Slotwinski [62] 62 ± 9; 63 ± 9 - N 5, 50 - N N TNM ? 1 N Y t N
Gogos [47] 67 ± 17; 68 ± 20;
54 ± 25; 64 ± 16
P < 0.0001 52, 62,
57, 67, 64
P = 0.011 N APACHE
II
12 ± 7; 16 ± 9;
13 ± 8; 18 ± 8; 20 ± 5
3 N N N
Hoogerwerf [48] 57 ± 5, 66 ± 5 N*
(p < 0.0001)
63 50 N N APACHE
II
19 ± 2 1 N N N
Yousef [49] 44 ± 9 45 ± 9, 44 ± 10 N 59 60, 57 N N SOFA 12 (7 to 14) 3 (5) N N N
Turrel-Davin [50] 60 ± 4 ‘Age matched’ N 63 ‘Sex
matched’
N N SAPS II 51 ± 3 1 N N Y
Pelekanou [51] 69 ± 16 64 ± 20 0.099 64 43 0.300 N APACHE
II
18 ± 4; 15 ± 5 1 N N Y
Papadima [61] 66 ± 7; 67 ± 10 0.8 85, 47 0.54 N ASA I to II 1 Y t Y t Y t
Delogu [52] ? ? N ? ? N N ? ? 1 N N N
Weber [53] 56 ± 4 61 ± 5,? >0.05 68, 80 ? N N SAPS II 26 ± 2 1 N N Y
Roth [54] 56 ± 6 52 ± 14 N 66 ‘Matched’ N N APACHE N/S 1 N N N
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Table 6 Demographic information of lymphocyte apoptosis studies (Continued)
Le Tulzo [55] 55 ± 4; 64 ± 4 72 ± 4; 55 ± 4 N*
(p < 0.0001)
? ? N N SAPS II 33 ± 3; 58 ± 4 2 N N N
Hotchkiss [56] N/S N/S N 59 56, ? N N - 1 N N Y
Delogu [63] 47 ± 17 ‘Matched’ N ? ‘Matched’ N N ASA I to II 1 Y N Y t
Pellegrini [59] 44 (20–83) (18 to 60) N ? ? N N ISS 25 (9 to 59) 1 N N N
Delogu [64] ? ‘Matched’ N ? ‘Matched’ N N ASA I to II 1 N N Y t
Hotchkiss [60] 18 to 46 ? N 90 ? N N ISS N/S (9 to 50) 1 N N N
Hotchkiss [57] N/S N/S N 65 ? N N - 1 N N Y
Sasajima [65] 62 (55 to 74);
49(37 to 58)
N ? N N ? ? 1 N N N
Sugimoto [66] N/S N 50 N N ? ? 1 N N Y t
Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we
identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups
which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute
Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was
documented. A ‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology. ‘Matched’, paper provided no details but stated the control population was
matched to the study population.
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Table 7 Experimental conduct and exclusion criteria of neutrophil respiratory burst studies
Author Study
population
Sample timing Definition
of sepsis
Microbiology
results
provided
Independent
adjudication
of sepsis d
iagnosis
Exclusion criteria
immunosuppressive
disease
Exclusion
criteria
malignancy
Primary conclusion of study
(in relation to neutrophil
respiratory burst)
Time of
first sample
No.
samples
(time span)
Santos [12] Sepsis 72 h (Dx sepsis);
48 h (organ failure);
onset of septic shock
2 (7 days) 1 A,B,C N N Y Y Reactive oxygen species production by
neutrophils is increased in sepsis, and
[it] is associated with poor outcome
Gorgulu
[19]
Trauma 24 h (Hosp Adm) 1 2 A,B,C N N Y N Fas stimulation of septic neutrophils
promotes apoptosis and inhibits functionality,
partially by non-apoptotic signalling
Bruns [13] Sepsis
(cirrhotics)
24 h
(Hosp Adm)
1 5 Y N Y N [Within cirrhotic patients] augmented
neutrophil ROS release in response to
E. coli…becomes exhausted in the
presence of infection
Shih [20] Trauma 24 h
(Hosp Adm)
2 (3 days) N N N Y Y Plasma migration inhibitory factor is one
of the important factors responsible
for early neutrophil activation
Kasten [21] Trauma 48 to 72 h
(Post-trauma)
1 N N N Y N Following trauma, there are concurrent
and divergent immunological responses…
hyper-inflammatory response by the
innate arm…and hypo-inflammatory
response by the adaptive arm
Valente [22] Trauma 48 h
(Hosp Adm)
3 (5 days) N N N Y N Injury results in differences in innate
immune function in the elderly when
compared with controls
Kawasaki
[26]
Elective
surgery
Pre-insult 5 (4 days) N N N Y N The innate immune system is suppressed
from the early period of upper abdominal
surgery
Frohlich
[27]
Elective
surgery
Pre-insult 2 (end of
anaesth)
N n/a n/a Y Y [This study demonstrates] suppression of
neutrophil function by propofol in vitro
[but not] in vivo
Martins [14] Sepsis 48 h (ICU Adm) 1 1 B,C Y N Y Y Neutrophil function is enhanced
in patients with sepsis
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Table 7 Experimental conduct and exclusion criteria of neutrophil respiratory burst studies (Continued)
Barth [15] Sepsis ? 6 (5 days) 1C (>4d) Y N N N Endogenous G-CSF increases neutrophil
function in patients with severe sepsis
and septic shock
Mariano [16] Sepsis (renal
replacement
therapy)
? 4 (1 day) 1, B,D N N N N Sera from septic patients [demonstrate] an
enhanced priming activity on neutrophils
[that is] reduced by ultrafiltration
Quaid [23] Trauma 24 h
(Hosp Adm)
1 N N N N N [After severe trauma] IL-8 and GROα lose
the ability to regulate the TNFα induced
respiratory burst
Wiezer [28] Elective
surgery
Pre-insult 5 (7 days) “clinical
criteria”
N N Y N Patients undergoing liver resection have
an increased activation of leukocytes
compared with other major abdominal
surgery [that is partially reversed] by
endotoxin neutralisation…with rBPI21
Ahmed [17] Sepsis 72 h
(Proof of
infection)
1 1 A,B Y Y Y Y Septic patients deliver fewer neutrophils to
secondary inflammatory sites
Shih [29] Trauma/
Surgery
24 h (Hosp adm) 3+ (7 days) 1 A,B,C N N Y Y Surgery after [trauma] has no effect on the
priming of neutrophils
Ertel [24] Trauma 24 h
(Hosp adm)
2 (3 days) N N N Y N Severe trauma stimulates acute-phase
priming in neutrophils
Ogura [25] Trauma 24 h
(Post-trauma)
4 + 1 (21 days) 2 A B C Y N N N Severe trauma stimulates acute-phase
priming in neutrophils
Pascual [18] Sepsis 24 h
(ICU adm)
1 1 A C Y N N N Plasma of septic patients may have a
profound effect on neutrophil
response [and] differentiates
between sepsis and non-sepsis samples
Sample timing: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each
subject in total and over what time span? Sepsis criteria: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM
1992 Consensus Conference [73]; 2, ACCP/SCCM Consensus Conference 2001 [74]; 3, SSC Consensus Conference 2008 [75]; 4, CDC NNIC [86]; 5, Microbiology and clinical assessment; 6, Postmortem identification of
infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. Microbiology documentation:
Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of
subsequent information?
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Table 8 Experimental conduct and exclusion criteria of monocyte tolerance studies
Author Study
population
Sample timing Definition
of sepsis
Microbiology
results
provided
Independent
adjudication
of sepsis
diagnosis
Exclusion criteria
immunosuppressive
disease
Exclusion
criteria
malignancy
Primary conclusion of study
(in relation to monocyte
endotoxin tolerance)
Time of
first
sample
No. of
samples
(time span)
Liu [30] Sepsis ? 1 ? B C N N N N TLR4 stimulation and human sepsis
activate pathways that couple NAD+
and its sensor SIRT1 with epigenetic
reprogramming
Buttenschoen
[41]
Elective surgery Pre-insult 4 (2 days) N N N Y N Cytokine liberation of mononuclear
cells suggests a state of postoperative
endotoxin tolerance
Pachot [31] Sepsis 72 h
(onset sep shock)
2 1C Y Y N N CX3CR1 expression [is] severely
down-regulated in [septic] monocytes
and associated with lack of functionality
West [32] Sepsis 24 h (ICU adm) 1 1 A, E Y N N N Leukocytes of septic patients, but not SIRS,
show LPS tolerance
Harter [33] Sepsis ? 1 1 A B C Y Y N N Endotoxin tolerance in septic patients
does not depend solely on TLR-2 or
TLR-4 expression
Flohe [40] Surgery in
trauma patients
48 h (ICU adm) Mon, Thu. 1 A B C Y N Y Y Initial trauma [and] major secondary surgery
cause suppression of immune functions,
whereas minor surgery does not
Escoll [34] Sepsis 48 h
(onset sepsis)
1 1 A Y Y Y Y Monocytes from septic patients rapidly express
IRAK-M mRNA when stimulated with LPS
ex vivo [unlike healthy volunteers]
Heagy [39] ICU patients
(sepsis)
72 h (ICU adm) 1 5 N Y N N ICU patients with…endotoxin tolerance have
significantly poorer clinical outcomes
Calvano [35] Sepsis ? 1 1 E A Y N N N Cellular LPS hyporesponsiveness [cannot] be
ascribed to significant alterations in…
cell surface LPS binding proteins
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Table 8 Experimental conduct and exclusion criteria of monocyte tolerance studies (Continued)
Sfeir [36] Sepsis 24 (Sep Shock) 1 1C Y Y Y N Monocytes from patients with septic
shock exhibit persistent IL-10 release at a
time when TNF-α release is down-regulated
Kawasaki [42] Elective surgery Pre-insult 7 (7 days) N N N Y N LPS responsiveness…is altered from the
early period of surgery
Heagy [37] Sepsis 72 h (ICU adm) 1 5 Y Y N N Impaired TNF release may be a manifestation
of monocyte endotoxin tolerance and may
be useful to diagnose sepsis
Bergmann [38] Sepsis ? 1 B C N N N N The altered [TNF-α release] of septic blood to
catecholamines might be due to altered
reactivity of leukocytes
Sample timing: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each
subject in total and over what time span? Sepsis criteria: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM
1992 Consensus Conference [73]; 2, ACCP/SCCM Consensus Conference 2001 [74]; 3, SSC Consensus Conference 2008 [75]; 4, CDC NNIC [86]; 5, Microbiology and clinical assessment; 6, Postmortem identification of
infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. Microbiology documentation:
Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of
subsequent information?
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Table 9 Experimental conduct and exclusion criteria of lymphocyte apoptosis studies
Author Study
population
Sample timing Definition
of sepsis
Microbiology
results
provided
Independent
adjudication
of sepsis
diagnosis
Exclusion criteria
immunosuppressive
disease
Exclusion
criteria
malignancy
Primary conclusion of study
(in relation to lymphocyte
apoptosis)
Time of
first sample
No. samples
(time span)
Roger [43] Sepsis Before first abs 1 3 B C Y Y Y Y Concomitant T cell proliferation and T cell
apoptosis are observed in human sepsis
Bandyopadhyay
[58]
Trauma ? Every 4 days
(28 days)
N N N Y N CD47 triggering, SHP-1 mediated NFkB
suppression and elevated TRAIL levels
increase…T cell apoptosis
White [11] Sepsis 24 h (ICU
adm/positive BC)
2 (7 days) 1 B C N Y Y N Patients with infection and sepsis have
deficient IL-2 and IL-7 gene expression
White [11] Elective
surgery
(infective
complications)
Pre-insult 3 (5 days) 4 N Y Y N
Zhang [44] Sepsis 24 h (sep shock) 1 1C N N Y N The expression of PD-1 on T cells [is] up
regulated in septic shock
Guignant [45] Sepsis 48 h (sep shock) 3 (10 days) 1C Y Y N Y PD-1 related molecules may constitute
a novel immunoregulatory system involved in
sepsis-induced immune alterations
Vaki [46] Sepsis 12 h
(organ failure)
2 B C Y Y Y N These findings support…the existence of an
early circulating factor in severe sepsis/shock,
modulating apoptosis of CD4 lymphocytes
Slotwinski [62] Elective
surgery
Pre-insult 4 (7 days) N N N Y N Preoperative enteral immunonutrition prevents
postoperative decrease in lymphocyte subsets
Gogos [47] Sepsis 24 h
(signs of sepsis)
1 2 B C Y Y Y N Major differences of the early statuses of innate
and adaptive immune systems exist between
sepsis and severe sepsis/shock in relation the
underlying type of infection
Hoogerwerf [48] Sepsis 24 h
(dx sepsis)
1 2 A Y Y Y N In patients with sepsis, alterations in apoptosis
of circulating leukocytes occur in a cell-specific
manner
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Table 9 Experimental conduct and exclusion criteria of lymphocyte apoptosis studies (Continued)
Yousef [49] Sepsis ? 1 1 A B C N N Y N Percentage of apoptotic lymphocyte median
values [could be] an indicator of prognosis
and survival in critically ill patients
Turrel-Davin [50] Sepsis 48 h
(sep shock)
2 (5 days) 1C Y Y N N Pro-apoptotic genes BID and FAS appear to
constitute promising apoptosis markers
Pelekanou [51] Sepsis 24 h
(signs of sepsis)
1 1 2 A B C Y Y Y N Decrease of CD-4 lymphocytes…
is characteristic of sepsis arising in
ventilator associated pneumonia
Papadima [61] Elective
surgery
Pre-insult 2 (1 day) N - Y Y No alterations in lymphocyte counts [and]
subpopulations [following use of epidural
anaesthesia]
Delogu [52] Sepsis 24 h
(sep shock)
1 ? C Y N N N Blood caspase-1 elevated in sepsis. IL-6
correlates with apoptotic rate and caspase-9
expression in lymphocytes
Weber [53] Sepsis 4 h (sev sepsis) 1 1 B N N Y Y In early severe sepsis…induction of…
Bim,Bid,Bak and downregulation of Bcl-2
and Bcl-xl is observed
Roth [54] Sepsis ? 1 1 A B C N N N N These findings strongly suggest that in septic
patients Th1 T cells are selectively susceptible
to apoptosis
Le Tulzo [55] Sepsis +ve
microbiology
±3 days
2 (6 days) 1 B C E Y N N N Lymphocyte apoptosis is rapidly increased in…
septic shock…and leads to a profound and
persistent lymphopaenia associated with
poor outcome
Hotchkiss [56] Sepsis 6 h (death) 1 6 Y N Y N Capsase 9 mediates profound progressive loss
of B and CD4 T helper cells in [severe] sepsis
Delogu [63] Elective
surgery
Pre-insult 3 (4 days) N N N Y Y Surgical trauma is associated with a significant
but transient increase in lymphocyte
commitment to apoptosis
Pellegrini [59] Trauma ? 2/week
(until death/
discharge)
N N N N N Increased levels of apoptosis are not directly
associated with negative trauma patient
outcome
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Table 9 Experimental conduct and exclusion criteria of lymphocyte apoptosis studies (Continued)
Delogu [64] Surgical Pre-insult 3 (4 days) N N N Y Y Surgical trauma upregulates lymphocyte death
signalling factors and downregulates survival
factors. Increased apoptosis of CD8+ cells
maybe associated with greater risk of
postsurgical infection
Hotchkiss [60] Trauma 10 h
(injury to surgery)
1 N N N N N Focal apoptosis of intestinal epithelial and
lymphoid tissues occurs extremely rapidly after
injury
Hotchkiss [57] Sepsis 6 h (death) 1 6 Y Y N N Caspase-3 mediated apoptosis causes
extensive lymphocyte apoptosis in sepsis
Sasajima [65] Elective
surgery
Pre-insult 5 (7 days) N N N N N Transient T cell apoptosis occurs after major
operations
Sugimoto [66] Elective
surgery
Pre-insult 4 (4 days) N N N N N Enhanced FasL expression is likely to be
related to systemic inflammatory responses
induced during the perioperative period
Sample timing: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each
subject in total and over what time span? Sepsis criteria: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM
1992 Consensus Conference [73]; 2, ACCP/SCCM Consensus Conference 2001 [74]; 3, SSC Consensus Conference 2008 [75]; 4, CDC NNIC [86]; 5, Microbiology and clinical assessment; 6, Postmortem identification of
infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. Microbiology documentation:
Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of
subsequent information?
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comparable between studies and was most frequently defined by the severity of sepsis
(Figure 4). These triggers included hospital admission (1/26), ICU admission (5/26),
proof of infection (2/26), diagnosis of sepsis (5/26), onset of sepsis (14/26; 54%), onset
of organ failure (3/24) and onset of septic shock (7/26) - the remaining two samples
were from autopsy studies. Multiple criteria for sampling were often used and
Figure 2 Identification of experimental control groups. The specific details for Hospital/ICU patients are
detailed within Tables 1, 2 and 3. Within cohort study pre-insult baseline samples were taken from the study
population, allowing them to act as their own experimental control.
Figure 3 Documentation of patients’ comorbid disease.
Figure 4 Event trigger used for index blood sample to be taken within studies of septic patients.
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dependent upon the severity of patient illness. Approximately half of all studies (14/26;
58%) obtained an initial sample within 24 h of hospital admission. Similar patterns of
sample timing were described for trauma patients. Repeat samples were often under-
taken, but over highly variable intervals that were frequently not defined a priori. By
contrast, all 12 studies undertaken in the elective surgical setting obtained preoperative
control samples, with subsequent samples taken on predefined postoperative days.
Therapies as potential confounders
Commonly administered therapies in intensive care impact directly on immune func-
tion [8-10]. We assessed reporting of three of the commonest therapies with estab-
lished immunomodulatory properties and found that only up to a quarter of studies
documented their use (Figure 5). Specifically, these were sedative agents (4/57; 7%),
antibiotics (6/57; 11%) and steroids (15/57; 26%).
Experimental conduct and outcomes
There was no apparent relationship between the experimental context of studies and
the control groups that were explored (Tables 1, 2 and 3). There are, however, clear
associations between the study population studied and experimental outcome (Tables 1,
7, 2, 8, 3 and 9). For example, within the respiratory burst data, there is a consistent
increase in respiratory burst identified by sepsis studies. However, since none of these
studies used pre-illness samples, it is unclear if the change is a feature of sepsis, or the
study population in relation to healthy volunteers. The conflicting results reported by
the three surgical studies are difficult to interpret since each study uses a different burst
assay, and the magnitude/type of operation varies. Similar patterns are also evident
across the monocyte and lymphocyte studies.
Discussion
This systematic review has revealed several important issues in the design and
reporting of immunologic phenotype in intensive care/sepsis studies. The studies we
selected are representative of the current literature, covering the past 15 years of
work in three key areas of sepsis research. Following a preliminary Pubmed search,
Figure 5 Documentation of drug exposure of the study population.
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these three assays were chosen because they represent the most frequently investiga-
tion for each immune cell type. These limitations refer to the clinical aspects of the
study methodology rather than specific laboratory techniques that we did not assess.
These data suggest that the use of surgical patients to model critical illness may
overcome several key limitations.
Defining what constitutes an adequate control sample for the immunologic study of
sepsis is clearly highly challenging. Case–control studies are frequently used in sepsis re-
search. Our review suggests that case-control studies cannot easily determine whether the
observed differences in the experimental readout between the study and control groups is
due to sepsis per se, or other differences between the groups including age, comorbidities
and treatment interventions. Whereas cohort studies do allow pre-sepsis samples to be
taken, the majority of studies are conducted in healthy volunteers free of important co-
morbidities (e.g. heart failure, cirrhosis) that influence both the development of, and sur-
vival from, sepsis [71]. Furthermore, age-, gender- and ethnicity-related differences in
immune function are well documented [67-70], yet our data demonstrates that several
key demographic details for study and control populations were frequently not reported.
Finally, the presence of malignant disease - associated with immunosuppression [72] and
disproportionately represented in the ICU population of most healthcare systems - was
only documented in a minority of studies.
Sepsis is currently defined using clinical constructs that define syndromes, rather
than use biologic and/or molecular criteria. It remains unclear whether there are
biologically relevant differences between clinically defined subtypes of sepsis. In
other words, changes in immunophenotype associated with progression of sepsis to
severe sepsis/septic shock may merely reflect the consequences of clinical interven-
tions and/or indirect effects on organ function that partly reflect pre-existing comor-
bidities. Furthermore, the specific detection of pathogens, or pathogen-associated
molecular patterns, is likely to further impact on the robustness of immunopheno-
typing since the location and type of micro-organism both regulate host-immune re-
sponses [77,78]. We identified only one study that specified infection site and/or a
specific pathogen [34].
Critically ill patients are exposed to a range of therapeutic agents that have
well-described immunologic effects. Although immunomodulation by the majority of
these agents has been established in vitro, their role in confounding the septic immuno-
phenotype remains unclear. Nevertheless, a myriad of off-target, immune effects have
been established in pre-clinical in vivo models. Many antibiotics target mitochondria
and eukaryotic protein synthesis [79]. Steroids exert potent pro- and anti-inflammatory
properties - including inducing lymphocyte apoptosis [9]. Similarly, sedatives and anal-
gesics exert profound effects on immune cell function [80,81].
Our data suggest that surgical patients offer important potential advantages for
mechanistic studies of sepsis. The incidence of sepsis - as defined by conventional
clinical criteria - varies from 6.98% to 12.25%, depending upon the health care system
and database interrogated [82]. No other patient population allows the collection of
highly phenotyped data and individualised control samples prior to a defined traumatic
insult. Since the volume of surgery is huge and large scale outcome data can be
collected, potential limitations including comorbidities and concomitant therapies can
be controlled for.
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Conclusions
We found several important limitations in clinical design associated with translational
immunologic studies of human sepsis. Clinical design in mechanistic studies exploring
changes in immunophenotype may contribute to the lack of translational therapeutic
progress in intensive care medicine. Major elective surgery offers a potential model to
overcome many of these methodological limitations.
Take-home message
Systematic review suggests a critical re-evaluation in design of immunologic phenotyping
studies conducted in intensive care.
Tweet
Immunological investigation of septic patients presents methodological challenges that
are not considered by many recent studies.
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